NASDAQ$BNGO
BioNano Genomics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Bionano Genomics reported a strong Q3 2021 with record Saphyr shipments and installations and a significant revenue increase.
Bionano Genomics reported a 112% year-over-year increase in total revenue, reaching $4.7 million in Q3 2021. The company expanded its installed base of Saphyr systems and closed the acquisition of BioDiscovery, transitioning into a data solutions provider. They ended the quarter with $326.1 million in cash and short-term investments.
- Total revenue increased by 112% year-over-year to $4.7 million.
- Expanded the installed base of Saphyr systems from 121 to 141.
- Closed acquisition of BioDiscovery, transforming into a data solutions provider.
- Ended the quarter with $326.1 million in cash and short-term investments.
Headline financials
Revenue & EPS history
BioNano · Revenue · Quarterly
$4.66M
Revenue by segment
BioNano · $4.66M total across 2 segments · Q3 2021
- Product Revenue$3.3M+108.9%70.9%
- Service and Other Revenue$1.36M+120.0%29.1%
Forward guidance
Bionano Genomics anticipates achieving several milestones by the end of 2021, focusing on driving global adoption of Saphyr and advancing research and development initiatives.
Tailwinds
- Interim publication of results from pediatric clinical study in Q4 2021.
- Validation of LDTs by 3 sites in both prenatal and pediatric clinical studies in Q4 2021.
- Initial prototype of next gen high throughput Saphyr in Q4 2021.
- Reach installed base of 150 systems to achieve a 50% increase over year end 2020 in Q4 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-3.3%
Avg return
Earnings day
-6.2%
Avg return
5 days after
-8.0%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+15.5%
Q4 2018
Best reaction
-29.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -9.5% | — | |
| Q4 2025 | +0.9% | -20.5% | -17.1% | |
| Q3 2025 | +2.8% | +4.8% | +10.2% | |
| Q1 2025 | +2.9% | +0.8% | -2.4% | |
| Q4 2024 | +11.1% | +8.6% | +43.4% | |
| Q3 2024 | -3.4% | -11.5% | -7.7% | |
| Q2 2024 | -21.5% | -23.5% | -13.7% | |
| Q1 2024 | +2.7% | +7.3% | -9.4% | |
| Q4 2023 | +0.0% | -5.8% | -18.2% | |
| Q3 2023 | -7.0% | -10.5% | +2.8% | |
| Q2 2023 | -0.2% | -13.9% | -15.7% | |
| Q1 2023 | +6.9% | -9.6% | +0.0% | |
| Q4 2022 | -8.4% | -5.3% | -19.8% | |
| Q3 2022 | +2.7% | +2.2% | -6.3% | |
| Q2 2022 | +6.6% | +0.0% | +2.2% | |
| Q1 2022 | -16.1% | -24.2% | -10.8% | |
| Q4 2021 | +1.4% | -10.7% | +20.6% | |
| Q3 2021 | -9.8% | -13.7% | -44.4% | |
| Q2 2021 | +5.4% | +4.4% | -1.0% | |
| Q1 2021 | +13.9% | +22.8% | +59.9% | |
| Q4 2020 | -17.9% | -14.4% | -34.1% | |
| Q3 2020 | -7.4% | -5.4% | -10.7% | |
| Q2 2020 | -8.4% | -6.5% | -32.5% | |
| Q1 2020 | -8.4% | -11.8% | +21.6% | |
| Q4 2019 | -29.8% | -30.3% | -74.3% | |
| Q3 2019 | -2.1% | +17.8% | +24.4% | |
| Q2 2019 | -14.4% | -11.3% | -50.5% | |
| Q1 2019 | -11.3% | -17.0% | -28.1% | |
| Q4 2018 | +15.5% | +7.4% | -8.1% | |
| Q3 2018 | -6.0% | -5.7% | -11.9% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro